PTN
Price
$0.53
Change
-$0.01 (-1.85%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
14M
47 days until earnings call
RYTM
Price
$49.81
Change
-$2.15 (-4.14%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
3.15B
33 days until earnings call
Ad is loading...

PTN vs RYTM

Header iconPTN vs RYTM Comparison
Open Charts PTN vs RYTMBanner chart's image
Palatin Technologies
Price$0.53
Change-$0.01 (-1.85%)
Volume$1.89K
Capitalization14M
Rhythm Pharmaceuticals
Price$49.81
Change-$2.15 (-4.14%)
Volume$3.05K
Capitalization3.15B
PTN vs RYTM Comparison Chart
Loading...
PTN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTN vs. RYTM commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTN is a Hold and RYTM is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (PTN: $0.54 vs. RYTM: $51.96)
Brand notoriety: PTN and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTN: 142% vs. RYTM: 153%
Market capitalization -- PTN: $13.77M vs. RYTM: $3.15B
PTN [@Biotechnology] is valued at $13.77M. RYTM’s [@Biotechnology] market capitalization is $3.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTN’s FA Score shows that 0 FA rating(s) are green whileRYTM’s FA Score has 0 green FA rating(s).

  • PTN’s FA Score: 0 green, 5 red.
  • RYTM’s FA Score: 0 green, 5 red.
According to our system of comparison, RYTM is a better buy in the long-term than PTN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTN’s TA Score shows that 4 TA indicator(s) are bullish while RYTM’s TA Score has 4 bullish TA indicator(s).

  • PTN’s TA Score: 4 bullish, 4 bearish.
  • RYTM’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, RYTM is a better buy in the short-term than PTN.

Price Growth

PTN (@Biotechnology) experienced а -25.44% price change this week, while RYTM (@Biotechnology) price change was -4.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

PTN is expected to report earnings on May 20, 2025.

RYTM is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($3.15B) has a higher market cap than PTN($14M). RYTM YTD gains are higher at: -7.181 vs. PTN (-51.514). PTN has higher annual earnings (EBITDA): -26.62M vs. RYTM (-238.09M). RYTM has more cash in the bank: 321M vs. PTN (3.42M). PTN has less debt than RYTM: PTN (358K) vs RYTM (3.94M). RYTM has higher revenues than PTN: RYTM (130M) vs PTN (350K).
PTNRYTMPTN / RYTM
Capitalization14M3.15B0%
EBITDA-26.62M-238.09M11%
Gain YTD-51.514-7.181717%
P/E RatioN/AN/A-
Revenue350K130M0%
Total Cash3.42M321M1%
Total Debt358K3.94M9%
FUNDAMENTALS RATINGS
PTN vs RYTM: Fundamental Ratings
PTN
RYTM
OUTLOOK RATING
1..100
739
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
10038
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9658
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PTN's Valuation (73) in the Biotechnology industry is in the same range as RYTM (96). This means that PTN’s stock grew similarly to RYTM’s over the last 12 months.

RYTM's Profit vs Risk Rating (38) in the Biotechnology industry is somewhat better than the same rating for PTN (100). This means that RYTM’s stock grew somewhat faster than PTN’s over the last 12 months.

RYTM's SMR Rating (100) in the Biotechnology industry is in the same range as PTN (100). This means that RYTM’s stock grew similarly to PTN’s over the last 12 months.

RYTM's Price Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for PTN (96). This means that RYTM’s stock grew somewhat faster than PTN’s over the last 12 months.

PTN's P/E Growth Rating (95) in the Biotechnology industry is in the same range as RYTM (100). This means that PTN’s stock grew similarly to RYTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTNRYTM
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
70%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 18 days ago
81%
Bullish Trend 18 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
PTN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VSCIX106.63N/A
N/A
Vanguard Small Cap Index I
ANONX20.66N/A
N/A
American Century Small Cap Growth I
ETIMX14.20N/A
N/A
Eventide Balanced Fund Class I
GGICX12.75N/A
N/A
Goldman Sachs Global Infras C
NESNX56.92N/A
N/A
Natixis US Equity Opportunities N

PTN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTN has been loosely correlated with FATE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if PTN jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTN
1D Price
Change %
PTN100%
+9.66%
FATE - PTN
41%
Loosely correlated
+1.70%
VTGN - PTN
35%
Loosely correlated
+2.14%
MDGL - PTN
32%
Poorly correlated
+3.28%
AVCTF - PTN
30%
Poorly correlated
N/A
RYTM - PTN
30%
Poorly correlated
+3.92%
More